The next weight-loss drugs are moving quickly. Tolerability still sets the pace.

Metabolic health · Source date: November 2026 journal issue; indexed by November 2 · Evidence: Double-blind, randomized phase 2 trial · Primary source

Mazdutide acts on both GLP-1 and glucagon receptors. In a U.S. phase 2 study at 24 centers, 179 adults with overweight or obesity but without diabetes were assigned to weekly injections of several doses or placebo. This is an important step in the evolution of incretin-based therapies because it examines a distinct biological combination rather than simply increasing a familiar dose.

At 32 weeks, estimated mean weight changes were −7.3%, −15.6%, and −18.1% in the three treatment groups versus −0.9% for placebo. The higher-dose groups generated the largest reductions. However, treatment discontinuation because of adverse effects reached 20% at 16 mg, primarily owing to gastrointestinal problems. The trial’s primary analysis used a hypothetical efficacy estimand; it should not be confused with average real-world results in people who stop therapy. It also measured body weight rather than long-term cardiovascular events, muscle function, or survival.

Can people retain strength and daily function as they lose weight? This trial measured weight change; it cannot settle that question. Eli Lilly funded the trial.

clinical-outcomes superiority over established options.